Imidazole → 7-{2-Butyl-4-[4-(4-methoxy-phenoxy)-phenyl]-imidazol-1-yl}-1,2,3,4-tetrahydro-isoquinoline hydrochloride

HRID 17741

反応式

HRID 17741 の反応式
[CH3:1][O:2][C:3]1[CH:18]=[CH:17][C:6]([O:7][C:8]2[CH:13]=[CH:12][C:11]([C:14](=O)[CH3:15])=[CH:10][CH:9]=2)=[CH:5][CH:4]=1.BrC(Br)=O.[NH2:23][C:24]1[CH:33]=[C:32]2[C:27]([CH2:28][CH2:29][N:30](C(OC(C)(C)C)=O)[CH2:31]2)=[CH:26][CH:25]=1.N[C:42]([NH2:44])=O.[C:45]([Cl:51])(=O)[CH2:46][CH2:47][CH2:48]C.N1C=CN=C1>>[ClH:51].[CH2:45]([C:42]1[N:23]([C:24]2[CH:33]=[C:32]3[C:27]([CH2:28][CH2:29][NH:30][CH2:31]3)=[CH:26][CH:25]=2)[CH:15]=[C:14]([C:11]2[CH:12]=[CH:13][C:8]([O:7][C:6]3[CH:17]=[CH:18][C:3]([O:2][CH3:1])=[CH:4][CH:5]=3)=[CH:9][CH:10]=2)[N:44]=1)[CH2:46][CH2:47][CH3:48]

参加物

7

実験手順

1-[4-(4-methoxyphenoxy)phenyl]ethan-1-one (1 mmol) was brominated by General Procedure R1. The bromo ketone was condensed with 7-amino-2-Boc-1,2,3,4-tetrahydroisoquinoline following general procedure R2. The aminoketone intermediate was treated with n-pentanoyl chloride accoding to General Procedure R3. The product amide was then subjected to imidazole formation employing general procedure R4. The BOC group of the product was removed employing general procedure T1 to afford 7-{2-butyl-4-[4-(4-methoxy-phenoxy)-phenyl]-imidazol-1-yl}-1,2,3,4-tetrahydro-isoquinoline hydrochloride (yield 135 mg)

後処理

  1. customThe BOC group of the product was removed

出典と根拠

ORDレコード
ord-f2ab40e73e5c4a46b8f5db2675ce8fd1
出典データセット
uspto-grants-2010_06
特許番号
US07737285B2

関連ノート

読み込み中…